Uncategorized

The International Diabetes Federation, in collaboration with Sanofi’s Global Health Unit, is taking significant steps to improve access to diabetes care.

Hemogenyx Pharmaceuticals plc announces the submission of a complete response tothe previously announced Clinical Hold of the Investigational New Drug application to the US Food and Drug Administration for HEMO-CAR-T.

Onera raises over €30M in Series C funding Onera Health, a leader in sleep diagnostic and monitoring solutions, closed a €30M Series C financing round.

PolTREG S.A. announced it received a Notice of Allowance from the United States Patent and Trademark Office, covering the manufacturing of T-regulatory cells to treat Type-1 Diabetes, and ways the therapy is administered.

Halozyme Therapeutics, Inc. announced that Roche received European Commission marketing authorization of Tecentriq® SC co-formulated with ENHANZE®, Halozyme’s proprietary recombinant human hyaluronidase enzyme, rHuPH20.

InnoCare Pharma, a commercial-stage biotech company, announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for the Company’s B-cell lymphoma-2 inhibitor, ICP-248.

Menarini Silicon Biosystems, a pioneer of liquid biopsy and single-cell technologies, announced the recent publication of the STIC CTC trial data demonstrating the clinical utility of CTC count as an independent prognostic factor in advanced breast cancer.

Brain Navi announced the completion of the 100th case utilizing its neurosurgical navigation robot NaoTrac.

No longer on the periphery of the life sciences market, nonprofit groups are bridging the gaps in drug discovery and development.

After a quiet start to 2024, the FDA is expected to decide on three applications over the next two weeks, including one for a nasal powder migraine treatment.